WO2009006483A1 - Salts of potassium atp channel openers and uses thereof - Google Patents

Salts of potassium atp channel openers and uses thereof Download PDF

Info

Publication number
WO2009006483A1
WO2009006483A1 PCT/US2008/068936 US2008068936W WO2009006483A1 WO 2009006483 A1 WO2009006483 A1 WO 2009006483A1 US 2008068936 W US2008068936 W US 2008068936W WO 2009006483 A1 WO2009006483 A1 WO 2009006483A1
Authority
WO
Grant status
Application
Patent type
Prior art keywords
formula
salt
formulation
diazoxide
group consisting
Prior art date
Application number
PCT/US2008/068936
Other languages
English (en)
French (fr)
Inventor
Neil M. Cowen
Lain Dukes
Original Assignee
Essentialis, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
PCT/US2008/068936 2007-07-02 2008-07-01 Salts of potassium atp channel openers and uses thereof WO2009006483A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US94762807 true 2007-07-02 2007-07-02
US60/947,628 2007-07-02
US94920707 true 2007-07-11 2007-07-11
US60/949,207 2007-07-11
US95085407 true 2007-07-19 2007-07-19
US60/950,854 2007-07-19
US98625107 true 2007-11-07 2007-11-07
US60/986,251 2007-11-07

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN 200880105223 CN101795691A (zh) 2007-07-02 2008-07-01 钾atp通道开放剂的盐及其用途
CA 2692160 CA2692160A1 (en) 2007-07-02 2008-07-01 Salts of potassium atp channel openers and uses thereof
JP2010515241A JP2010532383A (ja) 2007-07-02 2008-07-01 カリウムatpチャネル開口薬の塩およびその使用
EP20080772317 EP2170341A4 (en) 2007-07-02 2008-07-01 Salts of potassium atp channel openers and uses thereof

Publications (1)

Publication Number Publication Date
WO2009006483A1 true true WO2009006483A1 (en) 2009-01-08

Family

ID=40226526

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/068936 WO2009006483A1 (en) 2007-07-02 2008-07-01 Salts of potassium atp channel openers and uses thereof

Country Status (6)

Country Link
US (2) US20090062264A1 (enIt)
EP (1) EP2170341A4 (enIt)
JP (1) JP2010532383A (enIt)
CN (1) CN101795691A (enIt)
CA (1) CA2692160A1 (enIt)
WO (1) WO2009006483A1 (enIt)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012030165A2 (ko) 2010-08-31 2012-03-08 서울대학교산학협력단 P P A R δ 활성물질의 태자재프로그래밍용도
US9757384B2 (en) 2005-04-06 2017-09-12 Essentialis, Inc. Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
US9782416B2 (en) 2004-08-25 2017-10-10 Essentialis, Inc. Pharmaceutical formulations of potassium ATP channel openers and uses thereof
US10058557B2 (en) 2014-11-14 2018-08-28 Essentialis, Inc. Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2374963T3 (es) * 2006-01-05 2012-02-23 Essentialis, Inc. Sales de agentes de apertura del canal de potasio dependiente de atp y usos de las mismas.
EP2343075A1 (en) * 2010-01-04 2011-07-13 Neurotec Pharma, S.L. Diazoxide for use in the treatment a central nervous system (CNS) autoimmune demyelinating disease
EP2819675A4 (en) 2012-02-27 2015-07-22 Essentialis Inc Salts of potassium atp channel openers and uses thereof
WO2014197753A1 (en) * 2013-06-08 2014-12-11 Sedogen, Llc Method of treating prader willi syndrome and conditions associated with low basal metabolic rate or hyperphagia
US20170189429A1 (en) * 2014-07-10 2017-07-06 Rhode Island Hospital Treating Arrhythmia with Mitochondrial-Targeted Antioxidants
CN106518804A (zh) * 2016-07-31 2017-03-22 北京梅尔森医药技术开发有限公司 一种二氮嗪新晶型及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140343A (en) * 1998-09-17 2000-10-31 Pfizer 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines
WO2006026469A2 (en) * 2004-08-25 2006-03-09 Essentialis, Inc. Pharmaceutical formulations of potassium atp channel openers and uses thereof
US7091225B2 (en) * 2000-12-20 2006-08-15 Smithkline Beecham Corporation Substituted oxazoles and thiazoles as hPPAR alpha agonists

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3269906A (en) * 1966-08-30 Imino-j,x-dihydro-l,z,x-benzothiadiazine- i,i-dioxides
US2678311A (en) * 1952-05-07 1954-05-11 Delmar Chem Theophylline salts
US2986573A (en) * 1961-01-18 1961-05-30 Schering Corp Method for the treatment of hypertension
US3304228A (en) * 1961-06-26 1967-02-14 Schering Corp Derivatives of 1, 2, 4-benzothiadiazine-1, 1-dioxides
US3265573A (en) * 1962-07-27 1966-08-09 Squibb & Sons Inc Benzothiadiazinesulfonamide-1, 1-dioxide composition
US3345365A (en) * 1964-03-31 1967-10-03 Schering Corp Novel 1, 2, 4-benzothiadiazine-1, 1-dioxide derivatives
US3431138A (en) * 1967-07-14 1969-03-04 American Cyanamid Co Method for coating pharmaceutical forms with methyl cellulose
ES442149A1 (es) * 1974-10-29 1977-04-01 Dainippon Pharmaceutical Co Procedimiento para preparar derivados de 1,2,4-benzotiadia- zino-1,1-dioxido.
US4184039A (en) * 1977-12-01 1980-01-15 Paul Finkelstein Benzothiadiazine 1, 1-dioxides
DE3530857A1 (de) * 1985-08-29 1987-03-05 Hoechst Ag Verfahren zur herstellung von niedrigviskosen celluloseethern
GB8601204D0 (en) * 1986-01-18 1986-02-19 Boots Co Plc Therapeutic agents
GB2186485B (en) * 1986-02-13 1988-09-07 Ethical Pharma Ltd Slow release formulation
US6361795B1 (en) * 1989-09-05 2002-03-26 Alza Corporation Method for lowering blood glucose
US5284845A (en) * 1991-03-14 1994-02-08 Paulsen Elsa P Use of oral diazoxide for the treatment of disorders in glucose metabolism
US5252338A (en) * 1991-06-27 1993-10-12 Alza Corporation Therapy delayed
US5378704A (en) * 1992-04-15 1995-01-03 E. R. Squibb & Sons, Inc. Non-peptidic angiotensin-II-receptor-antagonists
US5356775A (en) * 1992-07-29 1994-10-18 Brigham & Women's Hospital Primary structure for functional expression from complementary DNA of a mammalian ATP-sensitive potassium channel
US5629045A (en) * 1992-09-17 1997-05-13 Richard L. Veech Biodegradable nosiogenic agents for control of non-vertebrate pests
US5376384A (en) * 1992-12-23 1994-12-27 Kinaform Technology, Inc. Delayed, sustained-release pharmaceutical preparation
US5747278A (en) * 1993-05-21 1998-05-05 California Institute Of Technology DNA encoding inward rectifier, G-protein activated, mammalian, potassium KGA channel and uses thereof
US5965620A (en) * 1993-07-23 1999-10-12 Vide Pharmaceuticals Methods and compositions for ATP-sensitive K+ channel inhibition for lowering intraocular pressure
DK0705298T3 (da) * 1993-12-01 2002-07-08 Bioartificial Gel Technologies Inc Albuminbaseret hydrogel
US5744594A (en) * 1994-02-08 1998-04-28 Oregon Health Sciences University DNA encoding ATP-sensitive potassium channel genes
US5399359A (en) * 1994-03-04 1995-03-21 Edward Mendell Co., Inc. Controlled release oxybutynin formulations
FR2725623B1 (enIt) * 1994-10-18 1997-02-21
EP0778768B1 (en) * 1995-06-09 2004-05-26 Euroceltique S.A. Formulations and methods for providing prolonged local anesthesia
US6225310B1 (en) * 1996-01-17 2001-05-01 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
US6309855B1 (en) * 1996-02-08 2001-10-30 Centre National De La Recherche (Cnrs) Family of mammalian potassium channels, their cloning and their use, especially for the screening of drugs
EP1051977A1 (en) * 1997-11-10 2000-11-15 Hisamitsu Pharmaceutical Co. Inc. Release-sustaining agent for drugs and sustained-release pharmaceutical composition
WO2000004879A1 (en) * 1998-07-24 2000-02-03 Andrix Pharmaceuticals, Inc. Granule modulating hydrogel system
US6197976B1 (en) * 1998-12-14 2001-03-06 Syntex (U.S.A.) Llc Preparation of ketorolac
US6329367B1 (en) * 1998-12-18 2001-12-11 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
CA2356515A1 (en) * 1998-12-23 2000-07-06 G.D. Searle Llc Combinations for cardiovascular indications
US6197765B1 (en) * 1999-06-08 2001-03-06 Pnina Vardi Use of diazoxide for the treatment of metabolic syndrome and diabetes complications
US6436944B1 (en) * 1999-09-30 2002-08-20 Pfizer Inc. Combination effective for the treatment of impotence
US6313112B1 (en) * 1999-10-22 2001-11-06 Wake Forest University Methods of protecting neuronal function
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
FR2801587B1 (fr) * 1999-11-30 2002-01-11 Adir Nouveaux derives de benzothiadiazines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE10012199A1 (de) * 2000-03-13 2001-09-20 Haarmann & Reimer Gmbh Eingekapselte Substanzen mit kontrollierter Freisetzung
US6635277B2 (en) * 2000-04-12 2003-10-21 Wockhardt Limited Composition for pulsatile delivery of diltiazem and process of manufacture
WO2002000223A1 (en) * 2000-06-26 2002-01-03 Novo Nordisk A/S Use of potassium channel agonists for reducing fat food comsumption
CN1217787C (zh) * 2000-06-30 2005-09-07 微涂技术股份有限公司 聚合物涂层
GB0025473D0 (en) * 2000-10-17 2000-11-29 Pfizer Ltd Pharmaceutical combinations
US7560473B2 (en) * 2001-01-19 2009-07-14 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences, P.L.A. Amine derivative with potassium channel regulatory function, its preparation and use
US20030035106A1 (en) * 2001-04-09 2003-02-20 Chin-Te Yeh Phase-shifting alignment system
US20020173636A1 (en) * 2001-04-13 2002-11-21 Millennium Pharmaceuticals, Inc. 66784, a novel human potassium channel and uses therefor
DE10209979A1 (de) * 2002-03-07 2003-09-25 Ratiopharm Gmbh Arzneimittel mit Cholesterolspiegel-senkenden Wirkstoffen mit zeitverzögerter Wirkstofffreisetzung
CA2487416A1 (en) * 2002-06-10 2003-12-18 Metabolex, Inc. Methods and compositions for treating and diagnosing diabetes
US7902203B2 (en) * 2002-11-01 2011-03-08 Abbott Laboratories, Inc. Anti-infective agents
US20040097492A1 (en) * 2002-11-01 2004-05-20 Pratt John K Anti-infective agents
US7311727B2 (en) * 2003-02-05 2007-12-25 Board Of Trustees Of The University Of Arkansas Encased stent
US20040167197A1 (en) * 2003-02-26 2004-08-26 Rudolph Amy E. Compositions, combinations, and methods for treating cardiovascular conditions and other associated conditions
WO2004078113A3 (en) * 2003-03-04 2005-10-13 Michael Briggs Treatment and prevention of obesity with cox-2 inhibitors alone or in combination with weight-loss agents
US20040229803A1 (en) * 2003-04-22 2004-11-18 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders
US7378414B2 (en) * 2003-08-25 2008-05-27 Abbott Laboratories Anti-infective agents
JP2007505142A (ja) * 2003-09-10 2007-03-08 セダーズ−シナイ メディカル センター 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達
US20050075331A1 (en) * 2003-10-06 2005-04-07 Pratt John K. Anti-infective agents
WO2006000607A1 (es) * 2004-06-23 2006-01-05 Neurotec Pharma, S.L. Uso de activadores de los canales de katp (kco), en particular el diazóxido, en el tratamiento de la inflamación crónica de snc asociada a algunas efermedades
FR2877338B1 (fr) * 2004-11-03 2007-01-26 Servier Lab Nouveaux derives de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20060263805A1 (en) * 2005-03-16 2006-11-23 Andre Terzic Diagnosing and treating potassium channel defects
ES2374963T3 (es) * 2006-01-05 2012-02-23 Essentialis, Inc. Sales de agentes de apertura del canal de potasio dependiente de atp y usos de las mismas.
US20070254863A1 (en) * 2006-04-27 2007-11-01 Jochen Antel Use of CBx cannabinoid receptor modulators as potassium channel modulators

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140343A (en) * 1998-09-17 2000-10-31 Pfizer 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines
US7091225B2 (en) * 2000-12-20 2006-08-15 Smithkline Beecham Corporation Substituted oxazoles and thiazoles as hPPAR alpha agonists
WO2006026469A2 (en) * 2004-08-25 2006-03-09 Essentialis, Inc. Pharmaceutical formulations of potassium atp channel openers and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2170341A1 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9782416B2 (en) 2004-08-25 2017-10-10 Essentialis, Inc. Pharmaceutical formulations of potassium ATP channel openers and uses thereof
US9757384B2 (en) 2005-04-06 2017-09-12 Essentialis, Inc. Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
WO2012030165A2 (ko) 2010-08-31 2012-03-08 서울대학교산학협력단 P P A R δ 활성물질의 태자재프로그래밍용도
US10058557B2 (en) 2014-11-14 2018-08-28 Essentialis, Inc. Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome

Also Published As

Publication number Publication date Type
US20090062264A1 (en) 2009-03-05 application
JP2010532383A (ja) 2010-10-07 application
EP2170341A4 (en) 2010-12-01 application
CA2692160A1 (en) 2009-01-08 application
US20130040942A1 (en) 2013-02-14 application
CN101795691A (zh) 2010-08-04 application
EP2170341A1 (en) 2010-04-07 application

Similar Documents

Publication Publication Date Title
US20060029664A1 (en) Dosage form containing carbetapentane and another drug
US20040248942A1 (en) Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
US6297262B1 (en) Treatment of schizophrenia and psychosis
WO2007106708A2 (en) Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
EP0687472A2 (en) Potentiation of drug response by a serotonin 1A receptor antagonist
WO2007008752A2 (en) Sustained release pharmaceutical compositions for highly water soluble drugs
WO2000016798A1 (en) Use of non-peptidyl compounds for the treatment of insulin related ailments
US20060159747A1 (en) Telmisartan and hydrochlorothiazide combination therapy
US20080293777A1 (en) Weight Loss Treatment
WO2006063737A1 (en) Combination therapy comprising telmisartan and hydrochlorothiazide
US20030190353A1 (en) Low water-soluble venlafaxine salts
US20090076166A1 (en) Enterically coated cystamine, cysteamine and derivatives thereof
US20050220870A1 (en) Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
US20060051418A1 (en) Pharmaceutical formulations of potassium ATP channel openers and uses thereof
KR100812538B1 (ko) 약물 제어방출형 메트포르민-글리메피리드 복합제제
US20040235802A1 (en) Combinations comprising cox-2-inhibitors and aspirin
US20070202167A1 (en) Hyoscyamine dosage form
US7572789B2 (en) Salts of potassium ATP channel openers and uses thereof
US20110311624A1 (en) Formulations of histone deacetylase inhibitor and uses thereof
EP1728512A1 (en) Controlled-leaching preparation and process for producing the same
CN101516347A (zh) 包含二甲双胍和瑞格列奈的药物制剂
US20040034065A1 (en) Combination
US20110311620A1 (en) Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
WO2012148252A2 (es) Cocristales ionicos con base en metformina
KR101302883B1 (ko) 텔미사르탄을 유효성분으로 포함하는 안정성이 증가된 약제학적 조성물 및 그 제조방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08772317

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008272923

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2692160

Country of ref document: CA

ENP Entry into the national phase in:

Ref document number: 2010515241

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010515241

Country of ref document: JP

NENP Non-entry into the national phase in:

Ref country code: DE

ENP Entry into the national phase in:

Ref document number: 2008272923

Country of ref document: AU

Date of ref document: 20080701

Kind code of ref document: A